Hoth Therapeutics Inc

HOTH

Company Profile

  • Business description

    Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer’s or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).

  • Contact

    1177 Avenue of the Americas
    5th Floor, Suite 5066
    New YorkNY10036
    USA

    T: +1 646 756-2997

    https://www.hoththerapeutics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    3

Stocks News & Analysis

stocks

What did Morningstar subscribers buy and sell during February?

How the most traded shares stack up against our analysts views.
stocks

Paying more for new customers is a troubling sign for ASX share

Shares fall close to 18% after reporting higher marketing expenses.
stocks

10 US stocks with the largest fair value estimate increases during Q4 earnings

Semiconductor companies Sandisk, Teradyne, and Applied Materials saw the largest fair value hikes.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,164.900.100.00%
CAC 408,045.80121.93-1.49%
DAX 4023,815.75389.61-1.61%
Dow JONES (US)47,954.74784.67-1.61%
FTSE 10010,413.94153.71-1.45%
HKSE25,321.3471.860.28%
NASDAQ22,748.9958.50-0.26%
Nikkei 22555,278.061,032.521.90%
NZX 50 Index13,538.6179.28-0.58%
S&P 5006,830.7138.79-0.56%
S&P/ASX 2008,940.303.10-0.03%
SSE Composite Index4,108.5726.090.64%

Market Movers